Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis during a key MASH trial. While it helped with MASH resolution and weight ...

Altimmune Inc. (NASDAQ:ALT) saw its stock tumble by 37% after releasing topline data from its Phase 2b IMPACT trial ...

Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials. Click for my update of ALT stock.

Explore Altimmune stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ALT.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety outcomes.

Health news includes a cyberattack affecting patient care in London, Walgreens' financial success amid strategic changes, Pfizer's trial success, Altimmune's setback, Eli Lilly's competitive launch in ...